36C25624Q0716 Pylarify (Piflufolastat F18) or F18 Prostate-Specific Membrane Antigen (PSMA) equivalent at Michael E. DeBakey VA Medical Center (MEDVAMC) located in Houston, Texas.
BPA FOR PCR AND ANTIGEN COVID-19 TESTING Solicitation ID/Procurement Identifier: 19QA1022A0013 Ultimate Completion Date: Tue Apr 16 17:00:00 GMT 2024
This notice is strictly for research and information purposes only.Background and Objectives: The National Institute on Aging (NIA) is working to create a national resource of isogenic sets of Alzheimer’s Disease and Related Dementias mutated iPSC lines, complimented by foundational phenotypic data sets from differentiated disease-relevant cells derived from these lines.
As such, the MSEDF is focused on the identification of novel antibody sequences to generate chimeric antigen receptors, as well as novel T-cell receptors (TCRs) for adoptive therapy.To provide this technical support, the MSEDF utilizes an Attana 200 Cell system (Serial Number: AC200-11009) to determine molecular interactions and for the identification of novel antibodies and derived molecules.
Attached is the Signed and Approved J&A for your review.
Cross-cutting activities on vaccines include developing, implementing and evaluating guidelines for use of vaccines, standardization and quality assurance activities, and characterization of potential vaccine antigens.
The objective of this R&D contract is to provide a mechanism to evaluate the complete scope of immunotoxicity by determining: 1) whether chemical or therapeutic agents can modulate the immune response using a battery of in vitro tests to measure immune suppression or stimulation in response to human-relevant antigens; 2) whether chemical agents have the potential to induce allergic responses using in chemico and in vitro OECD guideline test methods
